Dialing in on pharmacological features for a therapeutic antioxidant small molecule

Kayla N. Green, Kristof Pota, G. Tircsó, Réka Anna Gogolák, Olivia Kinsinger, Collin Davda, Kimberly Blain, Samantha M. Brewer, Paulina Gonzalez, Hannah M. Johnston, Giridhar Akkaraju

Research output: Contribution to journalArticle

Abstract

The pyridinophane molecule L2 (3,6,9,15-tetraazabicyclo[9.3.1]penta-deca-1(15),11,13-trien-13-ol) has shown promise as a therapuetic for neurodegenerative diseases involving oxidative stress and metal ion misregulation. Protonation and metal binding stability constants with Mg2+, Ca2+, Cu2+, and Zn2+ ions were determined to further explore the therapeutic and pharmacological potential of this water soluble small molecule. These studies show that incorporation of an -OH group in position 4 of the pyridine ring decreases the pI values compared to cyclen and L1 (3,6,9,15-tetraazabicyclo[9.3.1]penta-deca-1(15),11,13-triene). Furthermore, this approach tunes the basicity of the tetra-aza macrocyclic ligand through the enhanced resonance stabilization of the -OH in position 4 and rigidity of the pyridine ring such that L2 has increased basicity compared to previously reported tetra-aza macrocycles. A metal binding preference for Cu2+, a redox cycling agent known to produce oxidative stress, indicates that this would be the in vivo metal target of L2. However, the binding constant of L2 with Cu2+ is moderated compared to cyclen due to the rigidity of the ligand and shows how ligand design can be used to tune metal selectivity. An IC50 = 298.0 μM in HT-22 neuronal cells was observed. Low metabolic liability was determined in both Phase I and II in vitro models. Throughout these studies other metal binding systems were used for comparison and as appropriate controls. The reactivity reported to date and pharmacological features described herein warrant further studies in vivo and the pursuit of L2 congeners using the knowledge that pyridine substitution in a pyridinophane can be used to tune the structure of the ligand and retain the positive therapeutic outcomes.

Original languageEnglish
Pages (from-to)12430-12439
Number of pages10
JournalDalton Transactions
Volume48
Issue number33
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Antioxidants
Metals
Molecules
Ligands
Oxidative stress
Alkalinity
Rigidity
Trientine
Neurodegenerative diseases
Protonation
Metal ions
Substitution reactions
Stabilization
Ions
Water
pyridine
cyclen

ASJC Scopus subject areas

  • Inorganic Chemistry

Cite this

Green, K. N., Pota, K., Tircsó, G., Gogolák, R. A., Kinsinger, O., Davda, C., ... Akkaraju, G. (2019). Dialing in on pharmacological features for a therapeutic antioxidant small molecule. Dalton Transactions, 48(33), 12430-12439. https://doi.org/10.1039/c9dt01800j

Dialing in on pharmacological features for a therapeutic antioxidant small molecule. / Green, Kayla N.; Pota, Kristof; Tircsó, G.; Gogolák, Réka Anna; Kinsinger, Olivia; Davda, Collin; Blain, Kimberly; Brewer, Samantha M.; Gonzalez, Paulina; Johnston, Hannah M.; Akkaraju, Giridhar.

In: Dalton Transactions, Vol. 48, No. 33, 01.01.2019, p. 12430-12439.

Research output: Contribution to journalArticle

Green, KN, Pota, K, Tircsó, G, Gogolák, RA, Kinsinger, O, Davda, C, Blain, K, Brewer, SM, Gonzalez, P, Johnston, HM & Akkaraju, G 2019, 'Dialing in on pharmacological features for a therapeutic antioxidant small molecule', Dalton Transactions, vol. 48, no. 33, pp. 12430-12439. https://doi.org/10.1039/c9dt01800j
Green, Kayla N. ; Pota, Kristof ; Tircsó, G. ; Gogolák, Réka Anna ; Kinsinger, Olivia ; Davda, Collin ; Blain, Kimberly ; Brewer, Samantha M. ; Gonzalez, Paulina ; Johnston, Hannah M. ; Akkaraju, Giridhar. / Dialing in on pharmacological features for a therapeutic antioxidant small molecule. In: Dalton Transactions. 2019 ; Vol. 48, No. 33. pp. 12430-12439.
@article{672b81d59a334a8eb179d9f568bad28f,
title = "Dialing in on pharmacological features for a therapeutic antioxidant small molecule",
abstract = "The pyridinophane molecule L2 (3,6,9,15-tetraazabicyclo[9.3.1]penta-deca-1(15),11,13-trien-13-ol) has shown promise as a therapuetic for neurodegenerative diseases involving oxidative stress and metal ion misregulation. Protonation and metal binding stability constants with Mg2+, Ca2+, Cu2+, and Zn2+ ions were determined to further explore the therapeutic and pharmacological potential of this water soluble small molecule. These studies show that incorporation of an -OH group in position 4 of the pyridine ring decreases the pI values compared to cyclen and L1 (3,6,9,15-tetraazabicyclo[9.3.1]penta-deca-1(15),11,13-triene). Furthermore, this approach tunes the basicity of the tetra-aza macrocyclic ligand through the enhanced resonance stabilization of the -OH in position 4 and rigidity of the pyridine ring such that L2 has increased basicity compared to previously reported tetra-aza macrocycles. A metal binding preference for Cu2+, a redox cycling agent known to produce oxidative stress, indicates that this would be the in vivo metal target of L2. However, the binding constant of L2 with Cu2+ is moderated compared to cyclen due to the rigidity of the ligand and shows how ligand design can be used to tune metal selectivity. An IC50 = 298.0 μM in HT-22 neuronal cells was observed. Low metabolic liability was determined in both Phase I and II in vitro models. Throughout these studies other metal binding systems were used for comparison and as appropriate controls. The reactivity reported to date and pharmacological features described herein warrant further studies in vivo and the pursuit of L2 congeners using the knowledge that pyridine substitution in a pyridinophane can be used to tune the structure of the ligand and retain the positive therapeutic outcomes.",
author = "Green, {Kayla N.} and Kristof Pota and G. Tircs{\'o} and Gogol{\'a}k, {R{\'e}ka Anna} and Olivia Kinsinger and Collin Davda and Kimberly Blain and Brewer, {Samantha M.} and Paulina Gonzalez and Johnston, {Hannah M.} and Giridhar Akkaraju",
year = "2019",
month = "1",
day = "1",
doi = "10.1039/c9dt01800j",
language = "English",
volume = "48",
pages = "12430--12439",
journal = "Dalton Transactions",
issn = "1477-9226",
publisher = "Royal Society of Chemistry",
number = "33",

}

TY - JOUR

T1 - Dialing in on pharmacological features for a therapeutic antioxidant small molecule

AU - Green, Kayla N.

AU - Pota, Kristof

AU - Tircsó, G.

AU - Gogolák, Réka Anna

AU - Kinsinger, Olivia

AU - Davda, Collin

AU - Blain, Kimberly

AU - Brewer, Samantha M.

AU - Gonzalez, Paulina

AU - Johnston, Hannah M.

AU - Akkaraju, Giridhar

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The pyridinophane molecule L2 (3,6,9,15-tetraazabicyclo[9.3.1]penta-deca-1(15),11,13-trien-13-ol) has shown promise as a therapuetic for neurodegenerative diseases involving oxidative stress and metal ion misregulation. Protonation and metal binding stability constants with Mg2+, Ca2+, Cu2+, and Zn2+ ions were determined to further explore the therapeutic and pharmacological potential of this water soluble small molecule. These studies show that incorporation of an -OH group in position 4 of the pyridine ring decreases the pI values compared to cyclen and L1 (3,6,9,15-tetraazabicyclo[9.3.1]penta-deca-1(15),11,13-triene). Furthermore, this approach tunes the basicity of the tetra-aza macrocyclic ligand through the enhanced resonance stabilization of the -OH in position 4 and rigidity of the pyridine ring such that L2 has increased basicity compared to previously reported tetra-aza macrocycles. A metal binding preference for Cu2+, a redox cycling agent known to produce oxidative stress, indicates that this would be the in vivo metal target of L2. However, the binding constant of L2 with Cu2+ is moderated compared to cyclen due to the rigidity of the ligand and shows how ligand design can be used to tune metal selectivity. An IC50 = 298.0 μM in HT-22 neuronal cells was observed. Low metabolic liability was determined in both Phase I and II in vitro models. Throughout these studies other metal binding systems were used for comparison and as appropriate controls. The reactivity reported to date and pharmacological features described herein warrant further studies in vivo and the pursuit of L2 congeners using the knowledge that pyridine substitution in a pyridinophane can be used to tune the structure of the ligand and retain the positive therapeutic outcomes.

AB - The pyridinophane molecule L2 (3,6,9,15-tetraazabicyclo[9.3.1]penta-deca-1(15),11,13-trien-13-ol) has shown promise as a therapuetic for neurodegenerative diseases involving oxidative stress and metal ion misregulation. Protonation and metal binding stability constants with Mg2+, Ca2+, Cu2+, and Zn2+ ions were determined to further explore the therapeutic and pharmacological potential of this water soluble small molecule. These studies show that incorporation of an -OH group in position 4 of the pyridine ring decreases the pI values compared to cyclen and L1 (3,6,9,15-tetraazabicyclo[9.3.1]penta-deca-1(15),11,13-triene). Furthermore, this approach tunes the basicity of the tetra-aza macrocyclic ligand through the enhanced resonance stabilization of the -OH in position 4 and rigidity of the pyridine ring such that L2 has increased basicity compared to previously reported tetra-aza macrocycles. A metal binding preference for Cu2+, a redox cycling agent known to produce oxidative stress, indicates that this would be the in vivo metal target of L2. However, the binding constant of L2 with Cu2+ is moderated compared to cyclen due to the rigidity of the ligand and shows how ligand design can be used to tune metal selectivity. An IC50 = 298.0 μM in HT-22 neuronal cells was observed. Low metabolic liability was determined in both Phase I and II in vitro models. Throughout these studies other metal binding systems were used for comparison and as appropriate controls. The reactivity reported to date and pharmacological features described herein warrant further studies in vivo and the pursuit of L2 congeners using the knowledge that pyridine substitution in a pyridinophane can be used to tune the structure of the ligand and retain the positive therapeutic outcomes.

UR - http://www.scopus.com/inward/record.url?scp=85071026081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071026081&partnerID=8YFLogxK

U2 - 10.1039/c9dt01800j

DO - 10.1039/c9dt01800j

M3 - Article

VL - 48

SP - 12430

EP - 12439

JO - Dalton Transactions

JF - Dalton Transactions

SN - 1477-9226

IS - 33

ER -